Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.47%
1,067.36
+4.96
+0.47%
—1,062.401,064.141,071.991,061.02——
SIXC
Communications
SIXC
Communications
SIXC
-0.54%
603.48
-3.26
-0.54%
—606.74606.74609.84602.33——
SIXE
Energy
SIXE
Energy
SIXE
+0.54%
1,244.93
+6.72
+0.54%
—1,238.211,236.601,247.741,232.10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.68%
1,730.38
+11.77
+0.68%
—1,718.611,723.231,741.481,717.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.33%
639.47
+2.10
+0.33%
—637.37638.27642.30638.27——
SIXR
Staples
SIXR
Staples
SIXR
+0.16%
854.95
+1.36
+0.16%
—853.59854.05858.19851.34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.11%
218.56
+0.23
+0.11%
—218.33218.33219.73217.15——
SIXT
Technology
SIXT
Technology
SIXT
+1.02%
3,631.59
+36.78
+1.02%
—3,594.813,620.103,657.473,615.34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.80%
915.77
+7.23
+0.80%
—908.54909.50917.35907.07——
SIXV
Health care
SIXV
Health care
SIXV
+1.19%
1,512.81
+17.81
+1.19%
—1,495.001,499.611,517.101,499.61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.41%
2,408.21
+9.90
+0.41%
—2,398.312,406.822,421.802,404.22——
ABVX:NASDAQ
Abivax SA
$121.99
-1.64%
(-2.04) 1D
$123.19
+0.98% (+1.20)
After hours
Closed: May 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
$125.00
High
$125.64
Low
$120.05
Mkt. cap
8.53B
Avg. vol.
933.14K
Volume
1.18M
52-wk high
$148.83
52-wk low
$5.59
Shares outstanding
79.70M
No. of employees
69
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees69
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.05M
639.00K
1.91M
1.30M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38.64M
55.42M
44.40M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.94M
27.34M
27.69M
-
Operating expense
47.54M
81.35M
73.56M
-
Total operating expenses
47.54M
81.35M
73.56M
-
Operating income
-46.50M
-80.71M
-71.65M
-
Other non operating income
2.66M
-74.20M
-4.96M
-
EBT including unusual items
-48.41M
-153.36M
-76.11M
-
EBT excluding unusual items
-48.41M
-153.36M
-80.84M
-
Income tax expense
-
-
5.85M
-
Effective tax rate
-
-
-7.68%
-
Other operating expenses
-46.00K
-1.40M
1.47M
-
Net income
-48.41M
-153.36M
-81.96M
-
Net profit margin
-4,624.07%
-23,999.69%
-4,282.13%
-
Earnings per share
-
-
-
-
Interest and investment income
190.00K
3.36M
1.19M
-
Interest expense
-3.52M
-4.21M
-15.27M
-
Net interest expenses
-3.33M
-852.00K
-14.08M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.47M
-80.63M
-70.76M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer